ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia

Recruiting

Phase 1

Phase 2

ALS20-101ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia

Sponsor:

Children's Hospital of Philadelphia

Code:

NCT06364774

Conditions

Beta-Thalassemia

Eligibility Criteria

Sex: All

Age: 18 - 35

Healthy Volunteers: Not accepted

Interventions

ALS20

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-29. This information was provided to ClinicalTrials.gov by Children's Hospital of Philadelphia on 2025-04-23.